Skip to Main Content

Amid controversy over equitable distribution of Covid-19 vaccines, a large coalition of socially minded investor groups has filed shareholder proposals urging large drug makers to take various steps that could ultimately widen access to their medicines in the U.S. and elsewhere.

The effort reflects ongoing frustration with the pharmaceutical industry over business practices that have often made it difficult for patients to obtain treatments, according to Meg Jones-Monteiro, program director for health equity at the Interfaith Center on Corporate Responsibility, a 300-member organization with combined assets of over $4 trillion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment